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Abstract
Introduction: Most paediatric antiretroviral treatments (ARTs) in Thailand are limited to tertiary care hospitals. To decentralize
paediatric HIV treatment and care, Chiangrai Prachanukroh Hospital (CRH) strengthened a provincial paediatric HIV care network
by training community hospital (CH) care teams to receive referrals of children for community follow-up. In this study, we
assessed factors associated with death and clinical outcomes of HIV-infected children who received care at CRH and CHs after
implementation of a community-based paediatric HIV care network.
Methods: Clinical records were abstracted for all children who initiated ARTat CRH. Paired Wilcoxon signed rank tests were used
to assess CD4% and virological change among all children. Cox proportional hazard models were used to assess factors
associated with death. Treatment outcomes (CD4%, viral load (VL) and weight-for-age Z-score (WAZ)) were compared between
CRH and CH children who met the criteria for analysis.
Results: Between February 2002 and April 2008, 423 HIV-infected children initiated ARTand 410 included in the cohort analysis.
Median follow-up for the cohort was 28 months (interquartile range (IQR) 12 to 42); 169 (41%) children were referred
for follow-up at CH. As of 31 March 2008, 42 (10%) children had died. Baseline WAZ (B 2( p 0.001)) and baseline CD4%
(B5% (p 0.015)) were independently associated with death. At 48 months, 86% of ART-naı ¨ve children in follow-up had
VLB400 copies/ml. For sub-group analysis, 133 children at CRH and 154 at CHs were included for comparison. Median baseline
WAZ was lower in CH children than in CRH children (p 0.001); in both groups,WAZ, CD4% and VL improved after ART with no
difference in rate of WAZ and CD4% gain (p 0.421 and 0.207, respectively).
Conclusions: Children at CHs had more severe immunological suppression and low WAZ at baseline. Community- and tertiary
care-based paediatric ART follow-ups result in equally beneficial outcomes with the strengthening of a provincial referral
network between tertiary and community care. Nutrition interventions may benefit children in community-based HIV treatment
and care.
Keywords: Paediatric HIV; HIV care network; paediatric HIV treatment outcomes; task shifting; decentralized HIV care; Thailand.
Received 2 February 2012; Accepted 30 August 2012; Published 11 October 2012
Copyright: – 2012 Rawiwan Hansudewechakul et al; licensee International AIDS Society. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
Introduction
Approximately 3.4 million children worldwide were living
with HIV in 2010, most of them in developing countries [1].
Untreated HIV infection progresses rapidly in children; more
than half of those with vertically acquired HIV infection die
before their second birthday [2,3]. The use of antiretro-
viral (ARV) therapy (ART) dramatically reduces HIV-related
morbidity and mortality, however, with children often surviv-
ing into adulthood in high-income countries [4 7]. Although
similar treatment outcomes and survival patterns have been
observed in developing countries [8,9], the rollout of ART
programs for children has been slow and mortality rates
have remained high. As of 2010, 455,700 children worldwide
were receiving ART, accounting for only 23% of ART-eligible
children, and an estimated 250,000 paediatric AIDS deaths
had occurred [1].
High paediatric AIDS death rates have been largely
attributed to the difficulties in identifying and treating
paediatric HIV in resource-limited settings. Thailand, despite
having a national ART program since 2000 [10], has been
facing similar challenges. Adult HIV treatment and care
has been decentralized to community-based settings, but
paediatric ART has generally remained in the tertiary care
setting because of a lack of paediatricians and other skilled
healthcare providers [11].
Chiangrai province has one of the highest HIV prevalence
rates in Thailand (Figure 1). HIV prevalence rate in women-
attending antenatal clinics in Chiangrai peaked at 8.0% in
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11995 before declining to 0.9% in 2007; by contrast, national
rates were 2.3% and 0.8% in 1995 and 2007, respectively.
The mother-to-child transmission rate declined from 24% in
1992 to 19% in 1997 [12,13] and to 10% in 2001 to 2003
following the introduction of zidovudine and then zidovudine
plus single-dose nevirapine, for prevention of mother-to-child
HIV transmission (PMTCT) [14].
Chiangrai Prachanukroh Hospital (CRH), a tertiary care
hospital, is the referral hospital for 16 community hospitals
(CHs) in the province. With increased access to ART, the
paediatric HIVcaseload at CRH increased from fewer than ten
patients in 2002 to more than 300 children in 2004. Each
year, 70 to 100 additional children become eligible for ART
[15]. This increase has a significant impact on staff workload,
and the centralization of services posed challenges to families
in rural areas, including high costs for transportation and
absences from school and work.To address these needs, CRH
strengthened a provincial paediatric HIV care network by
training CH staff to receive referrals of children for commu-
nity follow-up. This study assessed factors associated with
death and the clinical outcomes of children who received
care at CRH and CHs after implementation of a community-
based paediatric HIV care network.
Methods
Community-based paediatric HIV care and treatment
network
Between 2004 and 2006, CRH trained and mentored its 16
referral network CHs to provide holistic paediatric ART. CH
teams consisted of at least two healthcare professionals,
including nurses/counsellors, people living with HIV (PLHIV),
pharmacists, and physicians. CRH trainings supplemented
routine national trainings and included a review of paediatric
HIV treatment and care; observation of service provision at
CRH; demonstration of clinical and adherence monitoring;
and use of case record forms and education materials. CRH
and CH teams provide the same standard paediatric HIV
treatment and care following national guidelines [16], includ-
ing clinical assessment and laboratory monitoring, screening
for opportunistic infections (OIs), prophylaxis, adherence
assessments, and routine ARV dose adjustment and psycho-
social support. In complicated cases, such as severe adverse
Figure 1. Location and number of paediatric HIV cases on antiretroviral treatment in the Thailand Ministry of Public Health antiretroviral
treatment program and Chiangrai province, 2007.
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2drug reactions or ARV resistance, CHs consult by telephone
with the CRH team or refer children back to CRH for man-
agement. Due to the limited number of physicians in most
CHs, nurses usually provide leadership and clinical care,
often prescribing ARVs under general physician attendance.
Pharmacists and trained PLHIV promote ARV adherence,
monitor adverse drug reactions and provide psychosocial
support. After referring children for CH follow-up, mentoring
and regular communication between CRH and CH occur
through teleconferences, individual case consultations, email,
medical record review, PLHIV home visit record review and
on-site visits. Typically, a CRH team visited each CH three to
six months after training to ensure that care and treatment
was consistent with guidelines.
All children in this analysis initiated ART following the
Thai national ART guideline at CRH. Children residing in
community districts were referred for follow-up at CHs when
they were clinically stable, as evidenced by the absence of OIs
and improvements in weight and CD4%. Additional criteria for
referralincludedcaregiverwillingnesstohavethechildreceive
ARTat the CH. Children followed up at CHs were scheduled to
be seen by a paediatrician at CRH every six months for clinical
and CH service quality monitoring (or sooner, if they devel-
oped complications or signs of treatment failure).
Assessment of treatment outcomes
Clinical records were abstracted for all children initiated ART
at CRH and followed up at either CRH or a CH between
February 2002 and March 2008. Children without follow-up
data were excluded.
Adherence, weight and CD4% were assessed every six
months. Optimal adherence was defined as at least 95%
of pills or liquid medications taken (based on pill counts or
volume measurement). Children who did not bring back or
lost their pills were treated as missing data. The US Centers
for Disease Control and Prevention (CDC) classification of HIV-
related disease at ART initiation was used [17]. Weight-for-
age Z-scores (WAZ) were calculated using Thailand national
standards for height and weight. Three WAZ categories were
created based on World Health Organization (WHO) refer-
ences: ‘‘normal weight’’ (  2), ‘‘moderately underweight’’
( 3t o 2) and ‘‘severely underweight’’ (B 3). Changes
in WAZ, CD4% and viral load (VL) were calculated over the
48-month follow-up period. As routine VL testing was not
initially available, baseline VL was available in only a subset
of children who were participants in a separate prospective
observational cohort study. The median baseline VL was
determined for children who had their first VL test within one
month of enrolment at CRH, and the proportion of children
with VLB400 copies/ml was determined at 12 month
intervals for 48 months. Virological response was compared
in children who had a baseline and at least one follow-up VL
result.VL results were included if they fell within a six-month
window of the 12-month interval follow-up time point.
Overall crude mortality rates were calculated, as well as early
(death occurred within the first 90 days), intermediate (death
between 91 and 180 days) and late (death after 180 days)
mortality rates.
Sub-group analysis was performed to compare treat-
ment outcomes (WAZ, CD4% and viral suppression (VLB
400 copies/ml)) from children followed up at CRH and CHs.
To reduce potential bias of difference in virological response,
children were excluded from this sub-analysis (n 123)
if they had a history of previous ART (n 42), initiated
protease inhibitor (PI)-based ART (n 16) or were on ART for
less than six months (n 65) (Figure 2). Mortality was not
compared because of the absence of any deaths in the CH
group.
Statistical analysis
Data was extracted from a clinic-based Microsoft Access
database and analyzed using STATA (version 10, Stata
Corporation, College Station, TX) and SPSS (version 15, SPSS
Inc., Chicago, IL). Categorical variables were compared using
the Pearson x
2 test, and continuous variables were compared
using t-tests and non-parametric Wilcoxon rank-sum tests
as appropriate. Interquartile ranges (IQRs) were calculated
for median values, and 95% confidence intervals (CIs) were
calculated for means.Two-sided p-values were analyzed, with
p50.05 considered significant. Multiple imputations were
Children excluded from
comparison analysis
N=123* 
Children initiating ART at Chiangrai Prachanukroh Hospital (CRH)
N=410
Children in follow up at CRH
N=133 
Children referred for follow up
to a community hospital
N=154 
Sub-group analysis: compared changes in weight for age-z-score,
CD4 T-cell, viral load. 
Cohort main analysis: 
mortality rate and
associated risk factors  
*We excluded children in the sub-group if they were: ARV 
experienced; had follow up < 6 months, had any opportunistic 
infections; or were on a protease inhibitor-based regimen  
Figure 2. HIV-infected children participating in the HIV care network, Chiangrai, Thailand, 2002 to 2007.
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3done for CD4, clinical staging and WAZ to account for miss-
ing data. Imputation results were not significantly different;
therefore, only complete case results are presented.
Child-years of follow-up were calculated from the date of
ART initiation at CRH until the earliest of the following dates:
(a) death, (b) lost to follow-up or (c) 31 March 2008 (the
day when data was censored). Referral time was calculated
from the date of ART initiation to the date of referral to CHs.
Survival rates at 12-month intervals were calculated using the
Kaplan Meier estimator. Cox proportional hazard regression
models with backward stepwise regression were fit to iden-
tify risk factors for mortality. Schoenfeld residuals and scaled-
Schoenfeld residuals were plotted for both covariate-specific
and global tests to assess validity of model assumptions.
There was no evidence of violation of model assumptions in
all reported analyses. Clinical staging and baseline CD4 were
collinear; therefore, only CD4 was included in the model.
Spearman correlations were used to assess the association
between duration of treatment at CRH and WAZ and CD4%
outcomes in CH sub-groups.
This study was approved by the CRH Institutional Review
Board. CDC human subjects’ office approved this project as
research not involving human subjects. All identifiers were
removed from the dataset prior to analysis.
Results
Entire study cohort
During the study period, 423 children initiated ART at CRH.
Three hundred and thirty-four (86%) were born before 2000,
when the national PMTCT program was implemented, and
382 (92%) initiated ART in or after 2003, when ART became
accessible nationally. Thirteen (3%) children without follow-
up data were excluded from the analysis. Excluded children
had similar age, baseline CD4% and clinical staging and were
new to ART initiation. The baseline characteristics of 410
children are shown in Table 1. Two hundred and thirty-one
Figure 3. (a) Weight-for-age change in response to ART among children in follow-up at Chiangrai Prachanukroh Hospital (CRH) and
community hospitals, Chiangrai, Thailand, 2002 to 2007. (b) CD4 and virological responses to ART among children in follow-up at Chiangrai
Prachanukroh Hospital (CRH) and community hospitals, Chiangrai, Thailand, 2002 to 2007.
Note: Weight for age Z-score (WAZ) was significantly different (pB0.05) between patient groups at CRH and community hospitals at months
0 to 24.
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4(56%) and 70 (17%) children had follow-up data for more
than 24 and 48 months, respectively. As of 31 March 2008,
42 children (10%) had died and 368 (90%) remained on ART.
There was no lost to follow-up documented during the study
period. One child refused to continue ART but remained in
follow-up; eight children were transferred to other provincial
clinics when they changed residence.
One hundred and sixty-eight (41%) children were referred
to CHs for follow-up, contributing to a median follow-up time
of 18 months (IQR 12 to 30 months) in CHs. Of these, only
six (3.5%) were referred back for follow-up at CRH: three
because of treatment failure and three for management
of adverse events. After the CH referral program started
in October 2004, the median referral time decreased from
31 months (IQR 20 to 39) in children initiating ART before
October 2004 to 13 months (IQR 8 to 81) for children
initiating ART between October 2004 and September 2006
and to eight months (IQR 3 to 11) for children initiating ART
after September 2006.
When they initiated ART at CRH, 366 (90%) children were
ART-naı ¨ve. The median age at ART initiation was 8.6 years
(IQR 6.5 to 10.7 years), with only 12 (2.9%) children younger
than two years. Most children had advanced disease at
ART initiation as indicated by their weight, clinical stage and
immunological status (Table 1). Three hundred and forty-
one (83%) initiated a nevirapine-based regimen, 53 (13%)
an efavirenz-based regimen and 16 (4%) a PI-based regimen;
all those on a PI-based regimen were research study partici-
pants who transferred to the CRH program or were born to
single-dose nevirapine-exposed mothers. Three hundred
and four (74%) children had at least one parent died, and
149 (36%) had both parents died.
Table 1. Baseline
a characteristics of children initiating ART at Chiangrai Prachanukroh Hospital (CRH) and among those referred for
follow-up
b at CRH or community hospitals, Chiangrai, Thailand, 2002 to 2007
Variable
Entire cohort initiating
ART (n 410)
c
CRH follow-up
(n 133)
c
Community hospital
follow-up (n 154)
c p
d
Gender, n (%)
  Male 177 (43) 61 (46) 66 (43) 0.610
Baseline age, years
  Median (IQR) 8.6 (6.5 to 10.6) 8.0 (6.7 to 11.3) 8.0 (6.8 to 10.3) 0.455
Baseline HIV stage (%)
  N or A 131 (32) 51 (38) 50 (32)
  B 73 (18) 30 (23) 28 (18)
  C 125 (31) 33 (25) 61 (40) 0.05
Baseline WAZ score (%)
  B 3 SD 67 (16) 19 (14) 28 (18)
   3t o 2 SD 110 (27) 30 (23) 52 (34)
    2 SD 226 (55) 84 (63) 74 (48) 0.034
  Median (IQR)  1.9 ( 2.7 to  1.1)  1.6 ( 2.6 to  0.8)  2.1( 2.8 to  1.5) 0.001
Baseline CD4% (%)
  B5% 158 (39) 50 (38) 67 (44)
   5% 224 (55) 76 (57) 79 (51) 0.302
  Median (IQR) 6 (2 to 13) 6 (2 to 12) 5 (2 to 11) 0.303
Baseline viral load (copies/ml)
Median (n) 100,000 (n 79) 133,570 (n 38) 80,400 (n 22) 0.167
(IQR) (18,629,234,420) (49,380, 230,700) (17,622, 153,022)
CD4% (at referral
e)
  Median (IQR) * 20 (14 to 24) 20 (16 to 26) 0.342
WAZ score (referral
e) *
  Median (IQR)  1.3 ( 2.0 to  0.7)  1.6 ( 2.2 to  1.2) 0.003
Follow-up time, months
  Median (IQR) 28 (12 to 42) 35 (16 to 48) 29 (20 to 40) 0.417
aIncludes baseline characteristics for all variables with the addition of CD4% and weight-for-age Z score (WAZ) at time of referral.
bFollow-up groups include children eligible for CH follow-up and a comparable group who stayed in follow-up at CRH and meet inclusion criteria
(as defined in methods).
cMissing data; therefore, numbers and percents may not add to total.
dp-value for Pearson x
2 test or Wilcoxon rank-sum test as appropriate to compare CRH and community group.
e12-month time point assessment taken based on the median referral time of 14 months after ART initiation.
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5Treatment outcomes
The increase in WAZ score of all children in the cohort was
consistent, improving from a baseline median IQR of  1.9
( 2.7 to  1.1) to  1.4 ( 1.9 to  0.5) and  0.8 ( 1.6
to  0.3) at 24 and 48 months. The proportion of children
who were moderately and severely underweight decreased
from 27% and 17% to 14% and 1.8%, respectively, at 24 and
48 months. Adherence data was available in 89 to 97% of
children in follow-up. Of those, 96 to 100% reported at least
95% adherence throughout the follow-up period.The median
CD4 lymphocyte percent improved from a baseline of 6%
(IQR 2 to 13%) to 24% (IQR 20 to 29%) at 24 months and 26%
(IQR 22 to 31%) at 48 months. Greatest improvement was in
the first six months of treatment, during whichCD4% more
than doubled to a median of 15% (IQR 10 to 22%). Overall,
the proportion of children with severe immune suppression
(CD4B15%) decreased from 80% at ART initiation to 7.1% at
24 months and 4.8% at 48 months. However, less than half
(46%) of the children who enrolled with CD4 ofB5% had
CD4%]25% at 48 months. The virological response among
ART-naı ¨ve children on ART in follow-up at 12, 24, 36 and 48
months with VLB400 copies/ml was 158/174 (91%), 173/
186 (93%), 143/154 (93%) and 121/140 (86%), respectively
(Figure 3b).
Forty-two children (10%) died over the 1,016 child-years of
follow-up, representing a crude mortality rate of 4.1/100
child-years of follow-up (95%CI, 3.0 to 5.6). Most deaths
occurred soon after ART initiation: 25 (60%) children within
the first 90 days. Seventeen (40%) children died after 90
days, of which 7 (41%) died after 180 days.The early mortality
rate was 24.6/100 child-years (95% CI 15.8 to 36.7), the
intermediate mortality rate was 2.1/100 child-years (95% CI
1.2 to 3.3) and the late mortality rate was 0.9/100 child-years
(95% CI 0.4 to 2.2).
The cause of death was recorded for 30 (71%) of the 42
children who died. Fourteen deaths were due to bacterial
or viral respiratory tract infections, four to tuberculosis or
suspected tuberculosis, two to penicillosis, two to crypto-
coccus, one to cytomegalovirus, one to sepsis, three to other
HIV-related causes and three to non-HIV-related causes.
None of the children died while in follow-up at CHs or after
being referred back to CRH from a CH.
In univariate analysis of factors associated with mortality,
orphan status and baseline WAZ score, clinical stage and
immunologic status were significantly associated with death.
In multivariate analysis, only severe malnutrition (WAZB 3
SD) and severe immune suppression (CD4B5%) at baseline
remained independent predictors of mortality (Table 2).
Orphan status and clinical stage were not assessed in the
multivariate analysis because of non-significance in tests
for linear trend (p 0.37) and collinearity with immune
category, respectively.
Sub-groups analysis
In the sub-groups identified for comparison, the 133 and
154 children who received follow-up at CRH and CHs,
respectively, had similar ages, sex, duration of follow-up,
median baseline CD4%, median baseline VL and orphan
status (Table 1). CH children initiated ART with a significantly
lower median WAZ score than CRH children (p 0.001);
clinical stage had borderline significance (p 0.05) (Table 1).
At referral, median time on ART was 14 months (IQR 3 to 55).
There was no correlation between duration of ART at CRH
prior to referral and changes in WAZ and CD4% at 12, 24,
36 and 48 months.
Adherence data was available for 73 to 93% of CRH
children and 83 to 95% of CH children. CH and CRH children
had similar adherence levels (95 to 100% and 93 to 100%
of children had ]95% adherence, respectively, over the 48
months).
Thirty-eight (29%) CRH children and 22 (14%) CH children
had VL data at baseline and at least one follow-up visit.
At 12, 24 and 36 months follow-up, only 1 each out of the 37,
35 and 35 CRH children and none of the 20, 16 and 18
CH children, respectively, had VL 400 copies/ml. At 48
months, none of the 27 CRH children and 1 of the 18 CH
children had VL 400 copies/ml [Figure 3b]. There was no
difference in the rate of weight gain between CH and CRH
children (mean difference in WAZ score gain was 0.88 and
1.06 for CRH and CH children, respectively, p 0.421).
However, CH children not only had lower WAZ at baseline,
but also continued to have lower WAZ through 48 months,
although the difference was only significant through 24
months (p 0.042) [Figure 3]. There was no difference in
CD4% gain between CRH and CH children (median difference
was 19% and 21% [p 0.207], respectively) [Figure 3].
Discussion
This study describes the implementation and treatment
outcomes of a paediatric HIV care network linking public
sector provincial and community ART programs in northern
Thailand. Findings suggest that despite difficulties associated
with the administration of ART for HIV-infected children,
it is possible to achieve and sustain beneficial outcomes in a
decentralized ART program in resource-limited settings by
strengthening a network of tertiary- and community-based
care providers. This is demonstrated by high retention rates
and clinical and immunological improvements, despite the
fact that most children initiated ART only at the advanced
disease stage.
The study cohort represents a first group of children with
perinatally acquired HIV-infection in Thailand before the
national PMTCT was implemented in 2000 (86% born before
2000). The older age and severe immunological suppression
at ART initiation in this cohort were likely due to late diag-
nosis and referral for ART initiation; the national program for
early infant diagnosis started in 2007, and full access
to the national ART program started in 2003 to 2004 [10].
Therefore, 92% of children in this cohort initiated ART in or
after 2003. The finding that children at CHs had significantly
lower baseline WAZ and more advanced stage HIV infection
is likely due to the abovementioned reasons and the lower
in socio-economic status of families living in more rural
areas.
In this study, adherence level remained high among
children in follow-up at both CRH and CHs, and much of
the success of the paediatric care network may be attributed
to good adherence. Adherence requires special attention to
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6children because of the need for caregiver support, paedi-
atric formulations and palatable medications with easy
dosing schedules. Paediatric treatment is made more chal-
lenging as a result of the high level of adherence required
to prevent sub-optimal viral suppression, a risk factor for
development of HIV drug resistance [18,19] and mortality
[20]. Although comparison across studies should be done
with caution, this study reported better adherence than most
paediatric treatment programs, with several studies report-
ing 50 to 80% adherence [21 23]. The intensity and sup-
port given to patients and caregivers in this program
may explain the high level of adherence and suggest that
multiple approaches combining educational and behavioural
components are useful in achieving desirable adherence
levels [24].
Weight gain, VL and CD4% responses to ART in this
cohort compare favourably to other studies. A prospective
cohort study of 107 children in the neighbouring Chiang
Mai province reported similar responses [25]. In the
Paediatric AIDS Clinical Trials Group (PACTG) 219 study,
33% of children who initiated treatment with CD4B5%
reached normal levels after three years of treatment,
compared to 45% after four years in our study [26]. Both
the Chiang Mai and PACTG studies were conducted in
settings where clinical care was provided by paediatricians;
obtaining similar results in a community-based program
with non-paediatric and non-physician staff is quite en-
couraging.
The mortality rate of 4.1/100 child-years of follow-up with
most deaths occurring within the first three months of
treatment was comparable to other paediatric cohorts in
resource-limited countries [8,9,27,28 30], as was the asso-
ciation between advanced HIV-related disease and mortality
[9,20,23,24]. These findings underscore the importance of
early identification of HIV-infected children and timely ini-
tiation of ART. However, the finding that most children who
Table 2. Factors associated with mortality among all children initiating ARTat Chiangrai Prachanukroh Hospital, Chiangrai, Thailand,
2002 to 2007
Unadjusted analysis Adjusted analysis
Baseline variable Number of deaths (%) HR (95%CI) p HR (95%CI) p
Sex
Male 21 (11.9) 1 1
Female 21 (9.0) 0.7 (0.4 to 1.3) 0.311 0.7 (0.3 to 1.5) 0.342
Age (years)
B5 6 (9.4) 1 1 0.390
5 9.9 20 (9.8) 1.1 (0.4 to 2.7) 0.880 1.9 (0.4 to 8.7) 0.477
]10 16 (11.3) 1.2 (0.6 to 2.3) 0.585 1.4 (0.6 to 3.6)
Orphan status
Both parents alive 16 (15.1) 1 Not included
a
One parent died 9 (5.8) 0.4 (0.15 to 0.79) 0.014
Both parent died 17 (11.4) 1.2 (0.64 to 2.24) 0.579
ARV regimen
NVP-based 38 (11.1) 1
EFV-based 3 (5.7) 0.5 (0.14 to 1.52) 0.205
PI-based 1 (6.3) 0.8 (0.1 to 6.3) 0.838
Median WAZ score
  2 SD 11 (4.9) 1 1 0.470
 2t o 3 SD 16 (8.2) 1.7 (0.7 to 4.2) 0.224 1.5 (0.5 to 4.0) 0.000
B 3 SD 11 (23.9) 4.3 (2.2 to 8.2) 0.000 3.4 (1.3 to 9.1)
CD4 status
 5% 8 (3.6) 1 1
B5% 28 (17.8) 5.0 (2.4 to 10.0) 0.000 3.1 (1.2 to 7.7) 0.015
CDC clinical stage
Asymptomatic/mild 2 (15) 1
Moderate 4 (5.5) 3.6 (0.8 to 19.5) 0.142 Not included
b
Severe 21 (16.8) 6.6 (2.5 to 17.2) 0.000
Note: Cox proportional hazards models between baseline variables and death.
aNot included due to non-significance in test for linear trend.
bNot included in the multivariate analysis due to co-linearity with CD4 status.
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7stayed in follow-up had viral suppression and remained on
first-line ART through 48 months confirms the reported high
level of ART adherence and the importance of intensive
adherence support in this program [25]. The absence of
deaths among children followed up at CHs is not surprising
given that patients were referred when clinically stable,
typically at least six months after ART initiation.
Although not a direct comparison of tertiary and CH
treatment outcomes, study results are of interest, especially
given the strategy of WHO [31] to shift tasks to less spe-
cialized healthcare workers and thereby increase access to
care. The success of this model highlights its potential for
other settings with high HIV burdens and limited resources,
such a sub-Saharan Africa. Similar findings on improvement
of clinical and virological outcomes for decentralized care
for both adults and children have been reported in several
African countries [32 35]. Of note, the provision of adher-
ence support by non-clinical staff, mainly PLHIV, could off-set
the limited number of trained healthcare workers. The level
of adherence support in this program, however, is intensive,
and replicating it in less developed countries with higher
HIV burdens may prove challenging.
Although these results compare favourably with other
published literature, there were several limitations. Missing
data was probably due to a retrospective study designed
and utilized routine program data. However, in the multiple
imputative analyses, results and overall interpretations were
not changed. Some data, such as VL, were limited because
of programmatic reasons, and findings may not be gener-
alizable to the entire cohort. Although the rates and causes
of mortality are consistent with other studies, the incom-
pleteness of data limits the conclusions about cause-specific
mortality. Additionally, although efforts were made to objec-
tively compare treatment outcomes between children in
follow-up at CRH and CHs, the unmatched design, differences
in baseline WAZ, referral of patients based on the clinician’s
judgment and the willingness of the caregiver to have the
child receive ART in the CH, all may have limited the ability to
compare the two groups. Nevertheless, baseline age, gender
and clinical characteristics, with the exception of WAZ, were
similar between the groups. Finally, few young children and
infants in the entire cohort and only ART-naı ¨ve children were
included in the sub-group analysis; thus, findings may not be
generalizable to younger and ART-experienced children. The
median age of this cohort and the absence of young infants
reflect the increased uptake of PMTCT interventions [36] with
only 41 children (10%) in this cohort born with HIV-infection
after 2000.
In summary, this study demonstrates improvements in
clinical immunological and virological outcomes in children
followed up in a tertiary and community-based ART network,
over a long follow-up period. This study also suggests that
paediatric HIV care can be shifted from tertiary to commu-
nity-based settings when tertiary care staff initiate ART, train
community teams and consistently monitor and support
community staff work. This may help increase patient’s
access to treatment, while at the same time reducing
workload at overburdened tertiary hospitals.
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